Leukapheresis Market is Estimated to Account for US$ 93 Million By 2027, says nova one advisor

SHARE THIS ARTICLE

Latest Study on “Leukapheresis Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2027”.

The global Leukapheresis market size is expected to be worth around US$ 93 million by 2027, according to a new report by nova one advisor.

The global Leukapheresis market size was valued at US$ 62 million  in 2020 and is anticipated to grow at a CAGR of 9.2% during forecast period 2021 to 2027.

Get your Customized Research Report@ https://www.novaoneadvisor.com/report/customization/4377

Growth Factors:

 Leukopaks are enriched leukapheresis products that contain higher concentrations of leukocytes. The increasing incidence and prevalence of leukemia and growing demand for leukopaks for research applications are some of the factors driving the growth of these markets. However, the high cost of therapeutic leukapheresis and cellular therapies, stringent donor recruitment criteria, and long procedural time for leukapheresis are restraining the growth of this market to a certain extent.

Leukapheresis Products and Leukopaks Market Dynamics

Driver: Increasing incidence and prevalence of leukemia

Globally, the incidence of leukemia has risen significantly. According to the American Cancer Society, in 2021, there will be an estimated 61,090 new cases of leukemia in the US. It is also estimated that there will be an estimated 23,660 deaths in 2021 due to leukemia in the US. The incidence rate of leukemia in children has increased by 1% year-on-year from 2008 to 2020. It can be inferred that the rising incidence of hyperleukocytic leukemia will drive the number of therapeutic leukapheresis procedures conducted in the coming years and, thereby, support the growth of the leukapheresis market.

Restraint: High cost of therapeutic leukapheresis and leukopaks

The average price for apheresis devices ranges between USD 20,000 and USD 150,000. Hence, smaller blood banks and hospitals do not opt for this type of blood collection. Furthermore, qualified and skilled physicians/labor/nurses are also required for effective treatment and the collection/removal of WBCs using apheresis. All these factors make leukapheresis an expensive tool for short-term use. Similarly, the cost of leukapheresis at hospitals and cancer treatment centers is also very high as it incurs the additional cost of disposables—between USD 1,500 and USD 3,000 per patient. Therefore, the adoption of leukapheresis and leukopaks among small blood banks, research centers, and hospitals is very low, which, in turn, will restrain the growth of the leukapheresis market during the forecast period.

Opportunity: Leukapheresis for pediatric patients

Despite its therapeutic applications, the adoption of leukapheresis as a treatment, particularly for hyperleukocytic leukemia, is still low. However, the applications of therapeutic leukapheresis in the treatment of pediatric patients are becoming an area of focus for stakeholders in this sector. This can be mainly attributed to the side-effects and risks of conventional treatments such as chemotherapy for children. Leukapheresis can be used for both the treatment/removal of excess WBCs in pediatric lymphoma patients and the collection of stem cells from children for other cancer patients. The possibilities and advantages of leukapheresis in this application make it an area of focus in this market, particularly given that very few hospitals currently provide leukapheresis treatment for children in both developed as well as emerging markets.

Challenge: Blood transfusion safety in developing countries

WBC transfusions have associated risks of transmitting infectious agents such as HIV, HBV, HCV, and malaria. Infection through the blood supply is a major issue, especially in developing countries such as India, China, Brazil, and Argentina, where economic constraints often limit safety considerations during WBC transfusion procedures.
Testing blood for HIV and hepatitis B viruses is an integral part of the blood transfusion process across the globe; moreover, the necessity of this step is more pronounced in developing countries where the burden of these diseases is higher. Thus, ensuring blood safety is a major challenge faced by blood and blood component suppliers and healthcare institutions in developing countries.

The leukapheresis devices segment is expected to grow at the highest CAGR, in the leukapheresis products market by type, in the forecast period

Leukapheresis devices are used for the separation of white blood cells (leukocytes) from whole blood. These instruments are also used to develop leukoreduced blood cell products such as leukoreduced plasma and leukoreduced RBCs. The growth of the leukapheresis devices market can largely be attributed to the increasing number of therapeutic leukapheresis procedures conducted for the treatment of leukemia, immune-mediated inflammatory diseases, and inflammatory bowel diseases. The increasing adoption of leukapheresis instruments by blood collection centers is another major factor supporting market growth.

The centrifugal devices segment holds the largest share in the leukapheresis devices segment, in the forecast period.

The centrifugal devices segment holds the largest share in the leukapheresis devices segment in the forecast period. The increasing installation of centrifugal apheresis devices in hospitals for therapeutic apheresis, favorable reimbursement policies for therapeutic apheresis, and the increasing use of centrifugal apheresis for blood component donations by blood centers and hospitals are the major factors driving the growth of the centrifugal apheresis devices market. However, the higher cost of continuous apheresis in comparison with membrane separation is limiting the growth of this market to a certain extent.

Research applications is expected to grow at the highest CAGR in the leukapheresis products by application segment in the forecast period.

The research applications segment is expected to grow at the highest CAGR in the leukapheresis products, by application segment in the forecast period. The large share of this segment is attributed to the increasing adoption of leukapheresis products for the development of cell-based immunotherapies, the increasing and the increasing number of clinical trials using leukopaks as a starting raw material for the development of cell-based therapies.

In 2020, the blood component providers & blood centers segment accounted for the largest share of the leukapheresis products market

The blood component providers & blood centers segment accounted for the largest share of the leukapheresis products market in 2020.  The high share of this segment can be attributed to the increasing number of blood donations, growing demand for leukopaks for the development of CAR T-cell therapies, and the increasing demand for blood components in clinical conditions such as cancer.

The mobilized leukopaks segment accounted for the largest share of the leukopaks market, by type, in the forecast period.

Based type, the mobilized leukopaks segment accounted for the largest share of the leukopaks market in the forecast period. The large share of this segment can be attributed to the increasing demand for low-granulocyte and low-hematocrit contamination, high cell viability, and an increase in CD34+ cell frequencies for the development of immunotherapies.

The pancreatic cancer segment is growing at the highest CAGR in the leukopaks market, by application, in the forecast period.

Based on application, the pancreatic cancer segment is expected to grow at the highest CAGR in the forecast period. The high growth of this segment can be attributed to the high potential of CAR T Cell therapy in pancreatic cancer including its ability to be directed against novel epitopes and combined with other therapeutic regimens for the disease.

 Regional analysis:

The Asia Pacific is growing at the highest CAGR in the leukapheresis products and leukopaks market, by region in the forecast period. This high growth can be attributed to emerging markets in the Asia Pacific becoming prominent growth hotspots in the market due to factors such as the rising geriatric population, the growing prevalence of leukemia, improving healthcare infrastructure, increasing number of clinical trials in China, and increasing public and private investments for the development of CAR-T therapy.

Buy Complete Assessment of Leukapheresis market Now@ https://www.novaoneadvisor.com/report/checkout/4377

COVID-19 Impact on Leukapheresis Sales

Businesses today are operating in a dynamic environment. Earlier focus primarily concentrated on keeping pace with changing consumer preferences. COVID-19 outbreak was unprecedented and exposed vulnerabilities of various industries. Pandemic-induces obstacles also were registered in the Leukapheresis market.

Sales plummeted as COVID-19 gradually tightened its noose worldwide. Supply-chain disruptions caused massive losses, while demand took nose-dive as consumers remained indoors with affected countries implementing either partial or complete lockdown.

Gradual recovery however is on the cards with the roll out of vaccinations. Nonetheless, consecutive waves of the virus compelled businesses to stay prepared for the worst. As government and healthcare organizations successfully implement steps to contain the spread of COVID-19, industries have begun operations, albeit at a slow and more cautious pace.

Against this backdrop, Nova one advisor’s study predicts gradual recovery for the Leukapheresis market 2021 onwards. This trend will however continue through the course of the report’s assessment period

Key Players:

This report provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the Leukapheresis market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.

Some of the prominent players in the Leukapheresis market include:

Charles River Laboratories (US), AllCells, LLC (US), StemExpress, LLC. (US), Caltag Medsystems Limited (UK), Lonza Group AG (Switzerland), ZenBio (US), Precision for Medicine (US), BioIVT (US), Discovery Life Sciences (US), and Intelligent Tissue Group (US).

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

The research report categorizes the market into the following segments and subsegments:

Leukapheresis Products Market, By Type

  • Leukapheresis Disposables
  • Leukapheresis Devices
    • Centrifugal Devices
    • Membrane Separators

Leukapheresis Products Market, By Application

  • Research Applications
  • Therapeutic Applications

Leukapheresis Products Market, By End User

  • Blood Component Providers & Blood Centers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Hospital & Transfusion Centers

Leukopaks Market, By Type

  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks
  •  Diseased Leukopaks
  • Isolated PBMCs

Leukopaks Market, By Application

  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks
  •  Diseased Leukopaks
  • Isolated PBMCs

Leukopaks Market, By Indication

  • Acute Lymphocytic Leukemia
  • Multiple Myeloma
  •  Non-Hodgkin’s Lymphoma
  • Chronic Lymphocytic Lymphoma
  • Pancreatic Cancer
  • Hepatocellular Carcinoma
  • Other Indications

Leukopaks Market, By End User

  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology

Browse Complete Table of Content@ https://www.novaoneadvisor.com/toc/leukapheresis-market

Why Buy this Report?

The purpose of Nova one advisor’s Leukapheresis market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.

Download This Full Research Report, Click Here@ https://www.novaoneadvisor.com/report/checkout/4377

About Us

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@novaoneadvisor.com

Web: https://www.novaoneadvisor.com/

James Root

James Root have over 6+ years of experience working in business development, and customer retention. I’ve gained my experience through serving higher education, healthcare, automotive, aerospace, manufacturing, local government and hospitality businesses with technical solutions.

View all posts by James Root →

Leave a Reply

Your email address will not be published. Required fields are marked *